```html

Bile Duct Stones (Choledocholithiasis)

Overview

Choledocholithiasis, commonly called bile duct stones, occurs when gallstones migrate from the gallbladder into the common bile duct (CBD) or form directly within the duct. The CBD is the tube that carries bile from the liver and gallbladder to the duodenum, where it helps digest fats. When stones block this pathway, bile backs up, leading to pain, inflammation, infection, and potentially life‑threatening complications.

Who it affects: The condition is most prevalent in adults aged 40‑70 years, with a slight female predominance (about 60 % of cases). It occurs in up to 10‑15 % of patients who have gallstones and is more common in people of Hispanic, Native American, and Asian descent.<sup>1</sup> Although rare in children, it can appear in infants with congenital bile‑duct anomalies.

Prevalence: In the United States, an estimated 20,000–30,000 hospital admissions for choledocholithiasis occur each year, representing roughly 13 % of all admissions for biliary disease.<sup>2</sup> Worldwide, the incidence mirrors that of gallstone disease—about 10‑15 % of the adult population will develop gallstones, and of those, a notable minority will experience ductal migration.

Symptoms

Symptoms range from mild discomfort to an acute surgical emergency. Not every stone causes obvious signs, especially if it’s small or moves spontaneously. Common presentations include:

• Right upper‑quadrant (RUQ) abdominal pain – a steady, often colicky pain that may radiate to the right shoulder or back. Pain typically worsens after a fatty meal.
• Jaundice – yellowing of the skin and whites of the eyes caused by bilirubin buildup.
• Fever and chills – sign of cholangitis (infection of the bile duct).
• Dark urine and pale stools – bilirubin excreted in urine makes it dark, while lack of bile in the intestine lightens stools.
• Nausea and vomiting – occur secondary to pain or biliary congestion.
• Pruritus (itching) – excess bile salts deposited in the skin.
• Elevated heart rate (tachycardia) – often accompanies fever or severe pain.
• Unexplained weight loss – chronic obstruction can reduce appetite.

When stones cause a complete blockage, the classic “Charcot’s triad” (RUQ pain, fever, jaundice) may progress to “Reynolds’ pentad” with the addition of hypotension and altered mental status, indicating severe sepsis.

Causes and Risk Factors

Choledocholithiasis usually results from the migration of gallstones formed in the gallbladder. However, stones can also originate directly in the bile duct (primary choledocholithiasis). The following factors increase the likelihood of stone formation or migration:

Primary causes

• Gallstone disease – cholesterol‑rich or pigment stones in the gallbladder.
• Bile stasis – reduced flow due to prolonged fasting, rapid weight loss, or pregnancy.
• Infection – bacterial colonisation can promote pigment stone formation.
• Genetic predisposition – certain gallstone‑related genes (e.g., ABCG5/8) are more common in Hispanic and Native American groups.

Risk factors

• Female gender (estrogen increases cholesterol saturation in bile).
• Age > 40 years.
• Obesity (BMI ≥ 30 kg/m²) and metabolic syndrome.
• Rapid weight loss (e.g., after bariatric surgery or very low‑calorie diets).
• High‑fat, high‑cholesterol diet.
• Diabetes mellitus.
• Pregnancy (bile stasis from progesterone).
• Previous gallbladder surgery (especially if the cystic duct stump is left long).
• Primary sclerosing cholangitis or other chronic biliary diseases.
• Family history of gallstones.

Diagnosis

Because symptoms overlap with other hepatobiliary disorders, a systematic approach is required.

Initial assessment

• History & physical exam – focus on pain pattern, jaundice, fever, and risk factors.
• Laboratory tests – liver function panel (ALT, AST, ALP, GGT, bilirubin), CBC for leukocytosis, and inflammatory markers (CRP, ESR).

Imaging studies

• Transabdominal ultrasound (US) – first‑line; detects dilated CBD (>6 mm) and may visualize stones (echogenic with acoustic shadow). Sensitivity ≈ 70‑80 %.
• Magnetic resonance cholangiopancreatography (MRCP) – non‑invasive, highly sensitive (≈ 95 %) for stones, strictures, and anatomy.
• Endoscopic ultrasound (EUS) – excellent for small stones (<3 mm) and can be performed during the same session as therapeutic ERCP.
• Endoscopic retrograde cholangiopancreatography (ERCP) – both diagnostic and therapeutic; carries a 5‑10 % risk of pancreatitis, so it is reserved when intervention is planned.
• CT scan – useful if perforation or alternative diagnoses (e.g., pancreatic tumor) are suspected.

Scoring systems

In acute settings, the Tokyo Guidelines 2018 provide criteria for diagnosing acute cholangitis, which often co‑exists with choledocholithiasis. These include clinical, laboratory, and imaging components.

Treatment Options

Management aims to relieve obstruction, treat infection, and prevent recurrence. The approach varies with severity, stone size, patient comorbidities, and availability of expertise.

Acute management (when infection or severe obstruction is present)

• Antibiotics – start broad‑spectrum (e.g., ceftriaxone + metronidazole) and tailor once cultures return. Typical course: 3–5 days after biliary drainage.
• Urgent biliary drainage – most commonly via ERCP with sphincterotomy and stone extraction. Alternative drainage (percutaneous transhepatic biliary drainage or nasobiliary tube) is used if ERCP fails or is contraindicated.

Definitive stone removal

• Endoscopic Retrograde Cholangiopancreatography (ERCP) – standard of care. Techniques include:
  • Sphincterotomy – cutting the sphincter of Oddi to allow stone passage.
  • Balloon or basket extraction – capturing and pulling stones out.
  • Lithotripsy (electrohydraulic or laser) – breaking large stones into removable fragments.
  • Stent placement – temporary drainage if stones cannot be removed immediately.
• Laparoscopic Common Bile Duct Exploration (LCBDE) – performed during a laparoscopic cholecystectomy; useful when stones are known pre‑operatively.
• Open surgical exploration – reserved for complex cases or when minimally invasive methods fail.

Adjunctive measures

• Cholecystectomy – removal of the gallbladder either during the same admission or electively after stone clearance reduces recurrence risk.
• Ursodeoxycholic acid (UDCA) – may dissolve small cholesterol stones, but its role in CBD stones is limited and generally not first‑line.
• Hydration and pain control – IV fluids and analgesics (e.g., acetaminophen, short courses of opioids) while definitive treatment is arranged.

Living with Bile Duct Stones (Choledocholithiasis)

After successful treatment, most patients return to normal activities, but ongoing care can prevent recurrence and manage lingering symptoms.

• Follow‑up imaging – an MRCP or ultrasound 4‑6 weeks post‑ERCP to confirm duct clearance.
• Monitor liver tests – periodic LFTs for 6‑12 months, especially if gallbladder remains.
• Dietary habits – adopt a low‑fat, high‑fiber diet to reduce cholesterol supersaturation.
• Weight management – aim for gradual weight loss (≤ 0.5 kg/week) to avoid rapid biliary stasis.
• Physical activity – regular aerobic exercise improves lipid profile and insulin sensitivity.
• Medication review – discuss with your doctor if you take drugs that affect bile composition (e.g., estrogen therapy, certain cholesterol‑lowering agents).
• Vaccinations – Hepatitis A and B vaccines protect the liver, especially if you had cholangitis.

Prevention

Because most CBD stones originate from gallbladder stones, preventing gallstone formation is key.

• Maintain a healthy body weight (BMI 18.5‑24.9 kg/m²).
• Eat a balanced diet rich in fruits, vegetables, whole grains, and healthy fats (e.g., olive oil).
• Limit saturated fat, trans fat, and cholesterol intake.
• Increase soluble fiber ( oats, beans, apples) to bind cholesterol in the gut.
• Stay hydrated – bile is less likely to become supersaturated with adequate fluid intake.
• Avoid extremely low‑calorie diets or rapid weight‑loss programs; aim for gradual change.
• If you have a history of gallstones, discuss elective cholecystectomy with your surgeon to eliminate the source of stones.
• Control metabolic conditions (diabetes, hyperlipidemia) with medication and lifestyle.

Complications

Untreated choledocholithiasis can lead to serious, sometimes life‑threatening problems:

• Acute cholangitis – bacterial infection of the bile ducts; can progress to sepsis.
• Ascending pancreatitis – stone obstruction at the ampulla can trigger pancreatic inflammation.
• Biliary cirrhosis – chronic cholestasis causing fibrosis and liver dysfunction.
• Secondary biliary stone formation – persistent stasis encourages new stone growth.
• Gallbladder carcinoma – long‑standing gallstones increase cancer risk; however, the direct link with CBD stones is weaker.
• Perforation or fistula – rarely, an impacted stone can erode through the bile duct wall.

When to Seek Emergency Care

References

1. Mayo Clinic. “Gallstones.” Updated 2023. https://www.mayoclinic.org/diseases-conditions/gallstones/
2. American College of Gastroenterology. “Guidelines for the Diagnosis and Management of Biliary Tract Disorders.” Gastroenterology, 2022.
3. World Health Organization. “Global Health Estimates 2022: Gallbladder and Biliary Disease.” WHO, 2023.
4. Tokyo Guidelines. “Management of Acute Cholangitis and Cholecystitis.” J Hepatobiliary Pancreat Sci, 2018.
5. Cleveland Clinic. “Choledocholithiasis (Common Bile Duct Stones).” 2024. https://my.clevelandclinic.org/health/diseases/
6. National Institutes of Health. “Ursodeoxycholic Acid (UDCA) – Clinical Uses.” 2023.

```